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1. Introduction 
Antiphospholipid antibody (aPL) is a heterogeneous group of autoantibodies directed 
against phospholipids-binding proteins. Antiphospholipid syndrome (APS) is defined by 
two major components: 1) presence of at least one type of aPLs, 2) the occurrence of at least 
one clinical feature from a list of potential disease manifestations, the most common of 
which are categorized as venous or arterial thromboses, and pregnancy complications. The 
pregnancy complications include recurrent spontaneous abortion (RSA), unexplained fetal 
death, severe pre-eclampsia, fetal growth restriction (FGR), and premature delivery. 
International consensus conferences have proposed and revised classification criteria for 
definite APS. Two types of aPLs were originally included in the laboratory criteria: IgG and 
IgM anticardiolipin antibody (aCL); and lupus anticoagulant (LA) (1). After that, IgG and 
IgM anti-β2 glycoprotein-I antibody (aβ2GPI) were included as laboratory criteria (2). 
However, scant evidence exists in regard to a relationship between the aPL profile and 
serious adverse pregnancy outcome. 
With the widespread use of tests to detect aPLs, obstetricians often encounter pregnant or 
non-pregnant women who have positive aPL tests. Currently, a variety of aPLs in the 
human blood can be measured by laboratory systems, each of which requires evaluation in 
regard to whether an association with pregnancy complications exists. This review focused 
on risks of pregnancy complications and therapeutic modality in women with aPLs. 
2. Antiphospholipid antibody and pregnancy complications 
The detrimental effects of aPLs are attributed to pathological mechanisms including 
thrombotic changes, suppression of hCG release (3), induction of complement activation 
and placental injury (4), and a direct effect on trophoblast cell growth and differentiation (5). 
Live-birth rates in women with aPLs (range 62–84%) are found to be lower than those in 
women without aPLs (range 90–98%) (6-9).  
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Many studies indicated that aPLs cause thromboembolism and mid-trimester fetal death; 
and probably RSA. However, the association between aPLs and risks of pregnancy-induced 
hypertension (PIH), pre-eclampsia, FGR, or premature delivery (PD) still remains 
controversial. In retrospective case-control studies, it was found that women with a history 
of severe pre-eclampsia or hemolysis-elevated liver enzymes-low platelets (HELLP) 
syndrome frequently tested positive for LA and aCL (10,11). However, prospective studies 
assessing associations between aPLs and PIH, pre-eclampsia or other pregnancy 
complications found conflicting results. Studies conducted in the 1990s noted that pre-
eclampsia was associated with the presence of LA (6), aCL (6, 9), β2–glycoprotein I 
dependent aCL (aCLβ2GPI) (12) and aβ2GPI (13). Similarly, fetal loss and FGR were 
associated with the presence of aCL (9, 12). Later prospective studies, however, denied the 
association between pre-eclampsia and the presence of LA (14), aCL (14-16) or aβ2GPI (16). 
PIH (17) and HELLP syndrome (16) were not associated with the presence of aCL or aβ2GPI.  
Our group have assessed whether aPLs measurements during early pregnancy are useful 
for predicting pregnancy complications (18). The aPLs including LA, IgG, IgM, IgA aCL, 
IgG, IgM phosphatidylserine dependent antiprothrombin antibody (aPS/PT), and IgG 
kininogen dependent antiphosphatidylethanolamine antibody (aPE) were measured 
during the first trimester in a consecutive series of 1,155 women. We for the first time 
determined predictive risks of pregnancy complications, being adjusted with the life style-
related confounding factors such as maternal age, parity, BMI, smoking and drinking. IgG 
aCL was asssociated with PIH; IgG aPE with PIH, severe PIH and PD; LA with PD and 
low birth weight (Table 1). Additionally, we found that multi-positive or double-positive 
aPLs (LA and aCL), were risk factor for severe PIH, PD and low birth weight. This is the 
first evidence in regard to the association between the multi/double-positive aPLs and 
severe PIH. Recent studies have also suggested that the multi-positive test is associated 
with a more severe course of APS disease, increasing significantly the rate of thrombosis 
(16, 19-21). Pregnant women with multi / double-positive aPLs should be more carefully 
managed during pregnancy.  
The abovementioned study for the first time demonstrated IgG aPE was associated with PIH 
(18). aPE was frequently detected in patients with unexplained recurrent early fetal loss, 
mid-to-late fetal loss, unexplained thrombosis, systemic lupus erythematosus, heart 
valvulopathies and livedo reticularis (22-26). Sugi et al. measured the kininogen dependent 
aPE that probably binds to kininogen as a cofactor (27). The kallikrein-kinin system is 
involved in the blood pressure control and angiogenesis. Tissue kallikrein cleaves low-
molecular-weight kininogen substrate to produce the vasodilator Lys-bradykinin, whereas 
plasma kallikrein forms bradykinin (BK) from high-molecular-weight kininogen (HMWK). 
Kininogen-deficient rats are susceptible to the development of salt-induced hypertension 
(28), and the in vivo angiogenesis is suppressed (29). The proangiogenic effect of BK and 
HMWK has been demonstrated in both in vitro and in vivo studies (30). Therefore, we 
assume that aPE pathophysiologically causes impairment of fetoplacental angiogenesis and 
vessel development, which subsequently may predispose women to PIH. Alternatively, 
disruption of kininogen cascade in the kallikrein-kinin system may reduce vasodilator 
production and cause a hypertensive disorder. A recent multicenter study demonstrated 
that aPE, but not LA or aCL, was closely associated with thrombosis with the highest odds 
ratio (31). The thrombotic insult may be causally associated with PIH. 
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PIH, pregnancy induced hypertension; aCL, anticardiolipin antibody; aPE, kininogen dependent 
antiphosphatidylethanolamine antibody; LA, lupus anticoagulant; 
Table 1. Antiphospholipid antibodies as risk factors for pregnancy complications 
determined by multivariate analysis 
Subsequently, whether IgG, IgM aβ2GPI was associated with the development of PIH or 
pre-eclampsia, we evaluated in the case-control study in cohort (32). The case group 
comprises 36 patients who developed PIH during their pregnancies. Normal ranges of IgG 
(<2.2 Unit/ml) and IgM (<6.0 Unit/ml) aβ2GPI values with cut-off values of 99th percentile 
have been established using non-pregnant 132 healthy controls. The cut-off values of IgG 
(normal <1.0 Unit/ml) and IgM (normal <1.2 Unit/ml) aβ2GPI were established from the 
most appropriate values dividing pregnant subjects in this study. It was found that titers of 
IgG aβ2GPI ≥1.0 Unit/ml represent a risk factor for severe PIH (P=0.023, OR 5.7 95%CI 1.4-
23). In addition, titers of IgM aβ2GPI ≥1.2 Unit/ml were found to be a risk factor for PIH 
(P=0.001, OR 8.8 95%CI 1.6-47.5). These results support the utility of aβ2GPI determination 
as one of the laboratory criteria for APS classification.  
There is a large body of evidence for an involvement of aβ2GPI in hypercoagulation status 
and thrombosis. (33-38). A multivariate analysis in a multicenter study has demonstrated 
that aβ2GPI and aPE, but not LA or aCL, were significantly associated with thrombosis (31). 
aβ2GPI induce the activation of endothelial cells, resulting in a proinflammatory state which 
favours the prothrombotic diathesis (39). Recently, a study has demonstrated β2GPI 
naturally inhibits von Willebrand factor (VWF)-dependent platelet adhesion and 
aggregation. aβ2GPI of APS patients neutralized the β2GPI-VWF interactions, contributing 
to hypercoagulation status in these patients (40). It is likely that the thrombotic insult of 
aβ2GPI to placental angiogenesis or circulation is causally associated with PIH. 
Additionally, β2GPI binds to trophoblast cells (41). The antibody binding to β2GPI 
downregulates trophoblast chorionic gonadotropin synthesis and secretion (42). Such a 
direct effect to trophoblast cells may contribute to inhibition of trophoblast invasiveness and 
defective placentation (41), causing PIH.  
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3. Antiphospholipid antibody and recurrent spontaneous abortion 
The mechanism of fetal loss is believed to be due to binding of aPLs to trophoblast cells, 
resulting in defective placentation.(43) Thromboembolic events in the uteroplacental 
circulation have also been proposed as a contributing mechanism(44). Jane et al. shown that 
complement activation plays an essential and causative role in pregnancy loss, and that 
blocking activation of the complement cascade rescues pregnancies using a mouse model of 
APS induced by passive transfer of human aPL (45).  
It remained uncertain whether any combination of aPL screening in women with RSA is 
clinically valid. Our group determined the prevalence of a variety of aPLs, with and without 
a combination of measurements, present in 114 women who had a history of two or more 
spontaneous abortions (Table 2). aPLs measured included LA, aCLß2GPI, aCL, aPS/PT and 
aPE. The most frequent type of aPL was IgG aPE (20.2%), followed by IgG aCL and then IgG 
aCLß2GPI. The standard combinations of aPL measurements upon RSA screening may be 
LA plus IgG, IgM aCLß2GPI, and LA plus IgG, IgM aCL. Using these standard 
combinations as definition, 2.6% and 4.4% of women with RSA could be diagnosed as 
having aPL. When IgA aCLß2GPI, IgA aCL and IgG, IgM aPS/PT were combined with the 
standard aPL measurements for RSA screening, positive frequencies of aPL reached 7.0%. If 
IgG, IgM aPE were additionally included, positive frequencies of aPL increased remarkably 
to 26.3% among women with RSA.  
 
aCL, anticardiolipin antibody; aCLβ2GPI, anticardiolipin β2-glyciprotein I antibody; aPS/PT, 
antiphosphatidylserine prothombin antibody; aPE, antiphosphatidylethanolamine antibody; LA, lupus 
anticoagulant. a,b,c,d,e,f,g   P<.05 
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The prevalence of each aPL and the combinations of aPLs was compared between women 
with RSA who had experienced at least one mid-trimester fetal loss and those who did not. 
As a result, RSA women with mid-trimester fetal losses yielded a significantly higher 
prevalence of LA, IgG, IgA aCLß2GPI, IgG aCL, and IgG aPS/PT, but not aPE, as compared 
with women with early RSA. Thus, it was confirmed that mid-trimester fetal losses were 
associated with the presence of LA, aCLß2GPI, aCL, and aPS/PT in women with RSA (Table 
2). The information provided here constituted a beneficial reference for clinical practice in 
the area of infertility.  
4. Management and therapy for women with antiphospholipid antibody 
The management of pregnancy in women with APS has been a subject of much debate, 
antiplatelet and anticoagulation therapies are usually recommended. A randomized 
controlled study demonstrated high live birth rate (71%) with low dose aspirin (LDA) plus 
unfractionated heparin (UFH) as compared with 42% with LDA alone in APS women (46). 
The LDA plus UFH had fewer maternal adverse effects, and was found to be superior to 
LDA plus steroids (47). American College of Chest Physicians guidelines recommend LDA 
in combination with prophylactic or intermediate-dose of UFH, or prophylactic dose of low 
molecular weight heparin (LMWH) for RSA women with aPL during their pregnancy (48).  
Figure 1 shows an algorithm used in the Kobe University Hospital for the management and 
treatment of pregnant women with positive test of aPLs (LA, aCL, aβ2GPI, or aCLβ2GPI). 
Treatment modalities are classified by a history or presence of thromboembolism (TE) and 
pregnancy complications. In women with aPL and no history, LDA is used until 28 weeks of 
gestation (GW). If women have a history of RSA in the first trimester, LDA is used until 28 
GW, plus use of prophylactic dose of UFH (5,000~10,000 U per day) until 15 GW is 
considered. In women with a history of IUFD, FGR and severe PIH, we recommend use of 
LDA until 28 GW plus UFH (10,000~12,000U per day) until 28-36GW. The timing of UFH 
completion can be determined due to a history of previous obstetric complications. In 
women with a history of TE event, warfarin should be substituted at 5 GW for LDA until 28 
GW plus therapeutic dose of UFH, and UFH (continuous infusion or subcutaneous injection 
to maintain the aPTT within the therapeutic aPTT ranges) is continued throughout their 
pregnancies. During pregnancy fetal growth and well-being are monitored by 
ultrasonography including pulse doppler and cardiotocogram; and maternal D-dimer is 
measured regularly.  If women have elevated D-dimer (especially ＞10.0 μg/ml), increases 
of UFH dose and ultrasound examination for deep venous thrombosis may be considered. If 
women yield multi-positive tests or a high titer of aPL, more intensive treatment should be 
considered (Figure 1).  
5. Intravenous immunoglobulin infusion for aspirin-heparin resistant 
antiphospholipid syndrome 
We often encountered APS women who underwent LDA plus heparin and failed to have a 
healthy infant. Such cases can be designated as aspirin-heparin resistant APS (AHRAPS) 
(49). In AHRAPS, intravenous immunoglobulin (IVIg) therapy may be effective. Carreras et 
al. (50) first reported successful IVIg therapy in a pregnant woman with LA and a history of 
9 RSA. A randomized controlled trial comparing LDA plus heparin plus IVIg with LDA  
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Antiphospholipid antibodies include lupus anticoagulant, anticardiolipin antibody, anti-β2 
glycoprotein-I antibody, and β2–glycoprotein I dependent anticardiolipin antibody. If women yield 
multi-positive tests or a high titer of antiphospholipid antibody, more intensive treatment should be 
considered as presented by dotted arrows. 
TE,  thromboembolism; RSA,  recurrent spontaneous abortion; IUFD,  intrauterine fetal death; FGR,  
fetal growth restriction; PIH,  pregnancy-induced hypertension; LDA,  low dose aspirin; UFH,  
unfractionated heparin; VD,  vaginal delivery; CS,  cesarean section 
Fig. 1. Management strategy for pregnant women with positive test for antiphospholipid 
antibody  
plus heparin therapies in 16 APS patients failed to show differences in the efficacy (51). 
Triolo et al. (52) reported that LDA plus low molecular weight heparin had a higher birth 
rate (84%) than that of IVIg alone (57%) in RSA women with aCLβ2GPI. But later, they also 
reported successful IVIg therapy in 8 of 10 APS women previously unresponsive to LDA 
plus heparin (53). There were several case reports of successful pregnancy outcome in APS 
patients with RSA (54-57). Therefore, a certain subgroup of APS women such as AHRAPS 
must have the possible advantage of IVIg therapy. The inhibitory effect of IVIg on aPLs, 
especially aCL, and LAC has been reported by several authors (58-61).  
The optimal dosage of IVIg in APS women during pregnancy was not determined and still 
to be debated. Yamada et al., first performed a high dose IVIg therapy (20 g/day, 5 
consecutive days, total 100 g) in early pregnancies of women with unexplained severe RSA, 
demonstrating a high live birth rate (62-64). Carreras et al. (50) performed IVIg therapy (400 
mg/kg・day, 5 consecutive days at 17 GW; and 2 days at 22, 27 GW) in APS women. Others 
reported monthly 1g/kg IVIg therapies (53). 
The mechanisms of IVIg efficacy for pregnant women with APS have not been fully 
assessed. Possible mechanisms to explain its broad activity comprised the following;  
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1) provision of anti-idiotypic antibodies and the function as immunomodulator; 2) 
interference with the complement activation and the cytokine network; 3) modulation of the 
expression and function of Fc receptors; and 4) differentiation and effector functions of T 
and B cells (65,66). As for the anti-idiotypic antibody function, inhibitory effects of IVIg on 
aCL and LA were reported (59,60,67). Caccavo et al. (67) demonstrated that aCL binding to 
cardiolipin was suppressed by F(ab’)2 fragments derived from IVIg in a dose-dependent 
manner. Galli et al. (59) also demonstrated dose-dependent suppression of LA activity in 
patients, using either IVIg or F(ab)2 fragments. IVIg may induce long-term decrease in 
autoantibody production by acquiring the inactivation of idiotype-bearing B cell clones (68). 
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